According to the research report, the global geriatric medicines market size is expected to touch USD 1,423.6 Billion by 2030, from USD 886.5 Billion in 2022, growing with a significant CAGR of 6.8% from 2022 to 2030.
The geriatric medicines report offers a
comprehensive study of the current state expected at the major drivers, market
strategies, and key vendors’ growth. The report presents energetic visions to
conclude and study the market size, market hopes, and competitive surroundings.
The research also focuses on the important achievements of the market, research
& development, and regional growth of the leading competitors operating in
the market. The current trends of the global geriatric medicines in conjunction
with the geographical landscape of this vertical have also been included in
this report.
The report offers intricate dynamics about
different aspects of the global geriatric medicines market, which aids
companies operating in the market in making strategic development decisions.
The study also elaborates on significant changes that are highly anticipated to
configure growth of the global geriatric medicines during the forecast period.
It also includes a key indicator assessment that highlights growth prospects of
this market and estimates statistics related to growth of the market in terms
of value (US$ Mn) and volume (tons).
Sample
Link @ https://www.precedenceresearch.com/sample/1690
| Report Coverage | Details |
| Market Size by 2030 | USD 1,423.6 Billion |
| Growth Rate from 2022 to 2030 | CAGR of 6.8% |
| Largest Market | North America |
| Fastest Growing Market | Asia Pacific |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segments Covered | Therapeutics, Condition, Distribution Channels, Route of Administration, Geography |
This study covers a detailed segmentation
of the global geriatric medicines market, along with key information and a
competition outlook. The report mentions company profiles of players that are
currently dominating the global geriatric medicines market, wherein various
developments, expansions, and winning strategies practiced and implemented by
leading players have been presented in detail.
Key Players
- GlaxoSmithKline PLC
- Novartis AG
- Pfizer Inc.
- Sanofi S.A.
- Bristol-Myers Squibb Company
- Boehringer Ingelheim GmbH
- Merck & Company Inc.
- Abbott Laboratories Inc.
- Eli Lilly & Company
- AstraZeneca PLC
Market Segmentation
- Analgesic
- Antihypertensive
- Statins
- Antidiabetic
- PPI
- Anticoagulant
- Antipsychotic
- Others
By Condition
- Cardiovascular
- Arthritis
- Neurological
- Cancer
- Osteoporosis
- Respiratory
- Others
By Distribution Channels
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
By Route of Administration
- Oral
- Parenteral
- Others
By Geography
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Malaysia
- Philippines
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC
- North Africa
- South Africa
- Rest of the Middle East & Africa
Research Methodology
The research methodology adopted by
analysts for compiling the global geriatric medicines report is based on
detailed primary as well as secondary research. With the help of in-depth
insights of the market-affiliated information that is obtained and legitimated
by market-admissible resources, analysts have offered riveting observations and
authentic forecasts for the global market.
During the primary research phase, analysts
interviewed market stakeholders, investors, brand managers, vice presidents,
and sales and marketing managers. Based on data obtained through interviews of
genuine resources, analysts have emphasized the changing scenario of the global
market.
For secondary research, analysts
scrutinized numerous annual report publications, white papers, market
association publications, and company websites to obtain the necessary understanding
of the global geriatric medicines market.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Geriatric Medicines Market
5.1. COVID-19 Landscape: Geriatric Medicines Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Geriatric Medicines Market, By Therapeutics
8.1. Geriatric Medicines Market, by Therapeutics Type, 2022-2030
8.1.1. Analgesic
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Antihypertensive
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Statins
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Antidiabetic
8.1.4.1. Market Revenue and Forecast (2017-2030)
8.1.5. PPI
8.1.5.1. Market Revenue and Forecast (2017-2030)
8.1.6. Anticoagulant
8.1.6.1. Market Revenue and Forecast (2017-2030)
8.1.7. Antipsychotic
8.1.7.1. Market Revenue and Forecast (2017-2030)
8.1.8. Others
8.1.8.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Geriatric Medicines Market, By Condition
9.1. Geriatric Medicines Market, by Condition, 2022-2030
9.1.1. Cardiovascular
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Arthritis
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Neurological
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Respiratory
9.1.4.1. Market Revenue and Forecast (2017-2030)
9.1.5. Osteoporosis
9.1.5.1. Market Revenue and Forecast (2017-2030)
9.1.6. Cancer
9.1.6.1. Market Revenue and Forecast (2017-2030)
9.1.7. Others
9.1.7.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Geriatric Medicines Market, By Distribution Channels
10.1. Geriatric Medicines Market, by Distribution Channels Type, 2022-2030
10.1.1. Hospital Pharmacies
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Online Pharmacies
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Retail Pharmacies
10.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Geriatric Medicines Market, By Route of Administration
11.1. Geriatric Medicines Market, by Route of Administration Type, 2022-2030
11.1.1. Oral
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Parenteral
11.1.2.1. Market Revenue and Forecast (2017-2030)
11.1.3. Others
11.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global Geriatric Medicines Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Therapeutics (2017-2030)
12.1.2. Market Revenue and Forecast, by Condition (2017-2030)
12.1.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)
12.1.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Therapeutics (2017-2030)
12.1.5.2. Market Revenue and Forecast, by Condition (2017-2030)
12.1.5.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)
12.1.5.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Therapeutics (2017-2030)
12.1.6.2. Market Revenue and Forecast, by Condition (2017-2030)
12.1.6.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)
12.1.6.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Therapeutics (2017-2030)
12.2.2. Market Revenue and Forecast, by Condition (2017-2030)
12.2.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)
12.2.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Therapeutics (2017-2030)
12.2.5.2. Market Revenue and Forecast, by Condition (2017-2030)
12.2.5.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)
12.2.5.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Therapeutics (2017-2030)
12.2.6.2. Market Revenue and Forecast, by Condition (2017-2030)
12.2.6.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)
12.2.6.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Therapeutics (2017-2030)
12.2.7.2. Market Revenue and Forecast, by Condition (2017-2030)
12.2.7.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)
12.2.7.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Therapeutics (2017-2030)
12.2.8.2. Market Revenue and Forecast, by Condition (2017-2030)
12.2.8.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)
12.2.8.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Therapeutics (2017-2030)
12.3.2. Market Revenue and Forecast, by Condition (2017-2030)
12.3.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)
12.3.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Therapeutics (2017-2030)
12.3.5.2. Market Revenue and Forecast, by Condition (2017-2030)
12.3.5.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)
12.3.5.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Therapeutics (2017-2030)
12.3.6.2. Market Revenue and Forecast, by Condition (2017-2030)
12.3.6.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)
12.3.6.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Therapeutics (2017-2030)
12.3.7.2. Market Revenue and Forecast, by Condition (2017-2030)
12.3.7.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)
12.3.7.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Therapeutics (2017-2030)
12.3.8.2. Market Revenue and Forecast, by Condition (2017-2030)
12.3.8.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)
12.3.8.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Therapeutics (2017-2030)
12.4.2. Market Revenue and Forecast, by Condition (2017-2030)
12.4.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)
12.4.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Therapeutics (2017-2030)
12.4.5.2. Market Revenue and Forecast, by Condition (2017-2030)
12.4.5.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)
12.4.5.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Therapeutics (2017-2030)
12.4.6.2. Market Revenue and Forecast, by Condition (2017-2030)
12.4.6.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)
12.4.6.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Therapeutics (2017-2030)
12.4.7.2. Market Revenue and Forecast, by Condition (2017-2030)
12.4.7.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)
12.4.7.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Therapeutics (2017-2030)
12.4.8.2. Market Revenue and Forecast, by Condition (2017-2030)
12.4.8.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)
12.4.8.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Therapeutics (2017-2030)
12.5.2. Market Revenue and Forecast, by Condition (2017-2030)
12.5.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)
12.5.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Therapeutics (2017-2030)
12.5.5.2. Market Revenue and Forecast, by Condition (2017-2030)
12.5.5.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)
12.5.5.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Therapeutics (2017-2030)
12.5.6.2. Market Revenue and Forecast, by Condition (2017-2030)
12.5.6.3. Market Revenue and Forecast, by Distribution Channels Type (2017-2030)
12.5.6.4. Market Revenue and Forecast, by Route of Administration Type (2017-2030)
Chapter 13. Company Profiles
13.1. GlaxoSmithKline PLC
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Novartis AG
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Pfizer Inc.
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Sanofi S.A.
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Bristol-Myers Squibb Company
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Boehringer Ingelheim GmbH
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Merck & Company Inc.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Abbott Laboratories Inc.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Eli Lilly & Company
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. AstraZeneca PLC
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1
774 402 6168
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
Blog: https://www.pharma-geek.com
0 Comments